Allogene Therapeutics, Inc. (ALLO) Bundle
An Overview of Allogene Therapeutics, Inc. (ALLO)
General Summary of Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. Founded in 2018, the company is headquartered in South San Francisco, California.
| Company Detail | Information |
|---|---|
| Founding Year | 2018 |
| Headquarters | South San Francisco, California |
| Stock Ticker | ALLO |
Key product pipeline includes:
- ALLO-501: CD19 CAR T cell therapy
- ALLO-715: Multiple myeloma CAR T cell therapy
- ALLO-316: Solid tumor CAR T cell therapy
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $39.4 million |
| Net Loss | $337.5 million |
| Cash and Investments | $596.3 million |
Industry Leadership
Allogene Therapeutics is a pioneer in allogeneic CAR T cell therapy development, focusing on innovative off-the-shelf cell therapies that could potentially transform cancer treatment approaches.
| Clinical Trial Stage | Number of Trials |
|---|---|
| Phase 1/2 Trials | 4 active trials |
| Solid Tumor Trials | 2 ongoing trials |
Mission Statement of Allogene Therapeutics, Inc. (ALLO)
Mission Statement of Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. focuses on developing innovative allogeneic CAR T cell therapies for cancer treatment.
Core Mission Components
| Component | Specific Details | Key Metrics |
|---|---|---|
| Research Focus | Allogeneic CAR T cell therapies | 7 clinical-stage product candidates |
| Target Indication | Hematologic and solid tumor cancers | Multiple phase 1/2 clinical trials |
| Innovation Approach | Gene editing technologies | $386.4 million cash and investments (Q3 2023) |
Research Pipeline Strategic Objectives
- Develop off-the-shelf CAR T cell therapies
- Utilize TALEN gene editing platform
- Target multiple cancer indications
Clinical Development Metrics
As of Q3 2023:
- Market Capitalization: $483.16 million
- Cash Position: $386.4 million
- Research and Development Expenses: $214.1 million (2022)
Key Product Candidates
| Product | Indication | Clinical Stage |
|---|---|---|
| ALLO-501 | Large B-cell Lymphoma | Phase 1/2 |
| ALLO-715 | Multiple Myeloma | Phase 1/2 |
Vision Statement of Allogene Therapeutics, Inc. (ALLO)
Vision Statement of Allogene Therapeutics, Inc. (ALLO)
Pioneering Allogeneic CAR T Cell Therapy LandscapeAllogene Therapeutics aims to revolutionize cancer treatment through off-the-shelf allogeneic CAR T cell therapies. As of Q4 2023, the company's vision focuses on developing transformative cell therapies targeting multiple cancer types.
Strategic Vision Components
Innovative Cell Therapy PlatformKey platform technologies include:
- ALPHA™ (Allogeneic Platform)
- SLICE™ Gene Editing Technology
- Universal CAR T Cell Manufacturing Strategy
Clinical Development Priorities
| Program | Cancer Type | Clinical Stage |
|---|---|---|
| ALLO-501 | Relapsed/Refractory Large B-Cell Lymphoma | Phase 1 Clinical Trial |
| ALLO-715 | Multiple Myeloma | Phase 1 Clinical Trial |
R&D Expenditure in 2023: $294.7 million
Technological Differentiation
Unique technological approaches include:
- Off-the-shelf allogeneic CAR T cell therapies
- Proprietary gene-editing techniques
- Scalable manufacturing processes
Financial Performance Indicators
| Metric | 2023 Value |
|---|---|
| Cash and Investments | $687.4 million |
| Net Loss | $336.2 million |
Core Values of Allogene Therapeutics, Inc. (ALLO)
Core Values of Allogene Therapeutics, Inc. (ALLO) in 2024
Innovation and Scientific Excellence
Allogene Therapeutics demonstrates commitment to innovation through substantial R&D investments.
| R&D Expenses (2023) | $323.4 million |
| Number of Active Clinical Trials | 7 ongoing trials |
| Patent Applications | 23 active patent families |
Patient-Centric Approach
Focused on developing advanced cell therapies for cancer treatment.
- Specialized in allogeneic CAR T cell therapies
- Targeting multiple cancer indications
- Developing off-the-shelf cell therapy solutions
Collaborative Research Ecosystem
Strategic partnerships drive scientific advancement.
| Research Collaborations | 4 active institutional partnerships |
| Academic Partnerships | 2 major research institutions |
Ethical and Transparent Operations
Commitment to regulatory compliance and scientific integrity.
- Full FDA compliance
- Regular internal and external audits
- Transparent clinical trial reporting
Financial Sustainability
Strategic financial management supporting research initiatives.
| Cash and Investments (Q4 2023) | $493.2 million |
| Annual Revenue (2023) | $12.6 million |
| Net Loss (2023) | $386.7 million |
Allogene Therapeutics, Inc. (ALLO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.